Statistics OFN (2023) Monthly mortality analysis, England and Wales: February 2023. https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/monthlymortalityanalysisenglandandwales/february2023#leading-causes-of-death
Bergmann M, Haasenritter J, Beidatsch D, Schwarm S, Hörner K, Bösner S et al (2021) Prevalence, aetiologies and prognosis of the symptom cough in primary care: a systematic review and meta-analysis. BMC Fam Pract 22:1–19
Hirons B, Rhatigan K, Kesavan H, Turner RD, Birring SS, Cho PS (2023) Cough in chronic lung disease: a state of the art review. J Thorac Dis 15(10):5823
Article PubMed PubMed Central Google Scholar
Çolak Y, Afzal S, Lange P, Laursen LC, Nordestgaard BG, Dahl M (2019) Role and impact of chronic cough in individuals with asthma from the general population. J Allergy Clin Immunol 7(6):1783–1792
Burgel P-R, Nesme-Meyer P, Chanez P, Caillaud D, Carré P, Perez T et al (2009) Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 135(4):975–982
Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR (2011) Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology 16(6):969–975
Gibson PG, Yang IA, Upham JW, Reynolds PN, Hodge S, James AL et al (2017) Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet 390(10095):659–668
Article CAS PubMed Google Scholar
Altenburg J, de Graaff CS, Stienstra Y, Sloos JH, van Haren EH, Koppers RJ et al (2013) Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. JAMA 309(12):1251–1259
Article CAS PubMed Google Scholar
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD Jr, Criner GJ et al (2011) Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365(8):689–698
Article CAS PubMed PubMed Central Google Scholar
Smith D, Du Rand IA, Addy C, Collyns T, Hart S, Mitchelmore P et al (2020) British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease. BMJ Open Respir Res 7(1):e000489
Article PubMed PubMed Central Google Scholar
Parker SM, Smith JA, Birring SS, Chamberlain-Mitchell S, Gruffydd-Jones K, Haines J et al (2023) British Thoracic Society Clinical Statement on chronic cough in adults. Thorax 78(Suppl 6):s3–s19
Pollock J, Chalmers JD (2021) The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther 71:102095
Article CAS PubMed PubMed Central Google Scholar
Hodge S, Reynolds PN (2012) Low-dose azithromycin improves phagocytosis of bacteria by both alveolar and monocyte-derived macrophagesin chronic obstructive pulmonary disease subjects. Respirology 17(5):802–807
Čulić O, Eraković V, Čepelak I, Barišić K, Brajša K, Ferenčić Ž et al (2002) Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 450(3):277–289
Bystrzycka W, Manda-Handzlik A, Sieczkowska S, Moskalik A, Demkow U, Ciepiela O (2017) Azithromycin and chloramphenicol diminish neutrophil extracellular traps (NETs) release. Int J Mol Sci 18(12):2666
Article PubMed PubMed Central Google Scholar
Ishida Y, Abe Y, Harabuchi Y (2007) Effects of macrolides on antigen presentation and cytokine production by dendritic cells and T lymphocytes. Int J Pediatr Otorhinolaryngol 71(2):297–305
Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik J, Jutz S et al (2014) Azithromycin suppresses CD4+ T-cell activation by direct modulation of mTOR activity. Sci Rep 4(1):7438
Article CAS PubMed PubMed Central Google Scholar
Broad J, Sanger GJ (2013) The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin. Br J Pharmacol 168(8):1859–1867
Article CAS PubMed PubMed Central Google Scholar
Sykes DL, Crooks MG, Hart SP, Jackson W, Gallagher J, Morice AH (2022) Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respir Med 202:106985
Morice AH (2013) Airway reflux as a cause of respiratory disease. Breathe 9(4):257–266
Song W-J, Morice AH (2017) Cough hypersensitivity syndrome: a few more steps forward. Allergy Asthma Immunol Res 9(5):394–402
Article CAS PubMed PubMed Central Google Scholar
Higgins J, Savović J, Page M, Elbers R, Sterne A (2022) Chapter 8: assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane 2020
Higgins JP, Li T, Deeks JJ (2019) Choosing effect measures and computing estimates of effect. In: Higgins JPT (ed) Cochrane handbook for systematic reviews of interventions. Wiley, Hoboken, pp 143–176
Berkhof FF, Hertog NED, Uil SM, Kerstjens HAM, van den Berg JWK (2013) Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir Res 14(1):125
Article PubMed PubMed Central Google Scholar
Hodgson D, Anderson J, Reynolds C, Oborne J, Meakin G, Bailey H et al (2016) The effects of azithromycin in treatment-resistant cough: a randomized, double-blind, placebo-controlled trial. Chest 149(4):1052–1060
Article PubMed PubMed Central Google Scholar
Guler SA, Clarenbach C, Brutsche M, Hostettler K, Brill AK, Schertel A et al (2021) Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis a randomized controlled crossover trial. Ann Am Thorac Soc 18(12):2018–2026
Cameron EJ, Chaudhuri R, Mair F, McSharry C, Greenlaw N, Weir CJ et al (2013) Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J 42(5):1412–1415
Article PubMed PubMed Central Google Scholar
Fraser SD, Thackray-Nocera S, Shepherd M, Flockton R, Wright C, Sheedy W et al (2020) Azithromycin for sarcoidosis cough: an open-label exploratory clinical trial. ERJ Open Res 6(4):1–7
Martin MJ, Lee H, Clayton C, Pointon K, Soomro I, Shaw DE et al (2019) Idiopathic chronic productive cough and response to open-label macrolide therapy: an observational study. Respirology 24(6):558–565
McGarvey LP, Birring SS, Morice AH, Dicpinigaitis PV, Pavord ID, Schelfhout J et al (2022) Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet 399(10328):909–923
Maher TM, Avram C, Bortey E, Hart SP, Hirani N, Molyneux PL et al (2023) Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evid 2:EVIDoa2300083
Wu Z, Spencer LG, Banya W, Westoby J, Tudor VA, Rivera-Ortega P et al (2024) Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial. Lancet Respir Med 12:273–280
Article CAS PubMed Google Scholar
Reynolds JE, Jetté ME, Wright ML, Sundar KM, Gillespie AI, Slovarp LJ (2023) Normative values for the leicester cough questionnaire in healthy individuals. Ann Otol Rhinol Laryngol 132(6):705–708
Faruqi S, Sykes DL, Crooks MG, Brindle K, Thompson J, Morice AH (2020) Objective assessment of cough: an early marker of response to biological therapies in asthma? Lung 198:767–770
留言 (0)